<DOC>
	<DOCNO>NCT00250679</DOCNO>
	<brief_summary>To evaluate long-term safety monitor long-term efficacy arformoterol period 6 month subject chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Safety Efficacy Arformoterol Tartrate Inhalation Solution Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This double-blind , double-dummy , multicenter , randomize , active-controlled , parallel group , outpatient , safety study evaluate long term safety arformoterol treatment subject COPD . Study participation approximately 6 month . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Key Male female subject must least 35 year old time consent Subjects must preestablished , document primary clinical diagnosis nonasthmatic COPD refer diagnosis nonasthmatic COPD Subjects must &gt; =15 packyear smoke history baseline breathlessness severity grade &gt; =2 ( Modified Medical Research Council [ MMRC ] Dyspnea Scale Score ) Visits 1 2 Female subject &lt; =65 year age must negative serum pregnancy test , females childbearing potential must use acceptable method birth control Subjects must general good health . Key Exclusion criterion : Subjects history asthma , exception asthma diagnose childhood Subjects blood eosinophil count &gt; 5 % total white blood cell count Subjects febrile illness within 72 hour ( 3 day ) Screening Visit 1 Subjects chest xray suggest diagnosis COPD ( e.g. , diagnostic pneumonia , infection , atelectasis , pneumothorax active/ongoing pulmonary condition )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>chronic bronchitis</keyword>
	<keyword>emphysema</keyword>
</DOC>